Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adjuvant therapy, with a predictive model AUC of 0.84.
Updated Basal Calcitonin Cutoffs Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer — Practical Thresholds for Surgery Planning

Updated Basal Calcitonin Cutoffs Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer — Practical Thresholds for Surgery Planning

A multicenter Chinese cohort of 509 initially treated MTC patients identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that better predict central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node metastasis than older guideline cutoffs.
Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries

Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries

A multinational time-series study across nine countries found increased short-term mortality after tropical cyclones for multiple causes — highest for renal disease and injuries — with larger effects in deprived and cyclone-naïve communities and stronger associations with cyclone-related rainfall.
Vernakalant Beats Procainamide for Rapid ED Cardioversion of Recent-Onset Atrial Fibrillation: Results from RAFF4

Vernakalant Beats Procainamide for Rapid ED Cardioversion of Recent-Onset Atrial Fibrillation: Results from RAFF4

The RAFF4 randomized trial found intravenous vernakalant superior to procainamide for rapid cardioversion of acute atrial fibrillation in the emergency department — higher conversion within 30 minutes, faster time to sinus rhythm, and fewer electrical cardioversions, with similar short-term safety.
CREST‑2: Stenting Reduces 4‑Year Ipsilateral Stroke vs Intensive Medical Therapy in Asymptomatic High‑Grade Carotid Stenosis; Endarterectomy Shows No Significant Benefit

CREST‑2: Stenting Reduces 4‑Year Ipsilateral Stroke vs Intensive Medical Therapy in Asymptomatic High‑Grade Carotid Stenosis; Endarterectomy Shows No Significant Benefit

In CREST‑2, patients with ≥70% asymptomatic carotid stenosis randomized to carotid‑artery stenting plus intensive medical therapy had fewer perioperative-or-ipsilateral strokes over 4 years than intensive medical therapy alone; carotid endarterectomy did not show a statistically significant advantage.
Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer

Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer

A multicenter Chinese cohort identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that stratify risk of central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node metastasis and improve prediction of structural recurrence-free survival versus ATA guidance.
Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

A BMJ systematic review and network meta‑analysis of 60 studies (4,633 patients) finds doublet chemotherapy combined with anti‑EGFR/BRAF therapy offers the best first‑line overall survival for advanced BRAF‑mutant colorectal cancer; anti‑EGFR/BRAF regimens remain optimal after prior therapy.
Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival, overall survival, or clinically meaningful reductions in grade ≥2 radiation toxicities, but estimates were imprecise.